{"analyses":[{"groupDescription":"Comparison of Rigors among arms.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","statisticalMethod":"Kruskal-Wallis","testedNonInferiority":false},{"groupDescription":"Comparison of Urinary Frequency among arms","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.006","statisticalMethod":"Kruskal-Wallis","testedNonInferiority":false},{"groupDescription":"Comparison of nausea among arms","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.030","statisticalMethod":"Kruskal-Wallis","testedNonInferiority":false},{"groupDescription":"Comparison of sweating among arms","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.062","statisticalMethod":"Kruskal-Wallis","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"17"}]}],"title":"Grade 1 or 2 rigors"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"29"}]}],"title":"Grade 1 or 2 urinary frequency"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"20"}]}],"title":"Grade 1 or 2 nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"33"}]}],"title":"Grade 1 or 2 sweating"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"description":"CTCAE Grading: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening, Grade 5=Death.","groups":[{"description":"Patients receive 1 capsule of placebo 2 times per day for 6 weeks and; patients receive 1 capsule of placebo 4 times per day for 6 weeks.","id":"OG000","title":"Collective Placebo"},{"description":"Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks.","id":"OG001","title":"Pilocarpine 2 Times Per Day"},{"description":"Patients receive 5mg of Pilocarpine 4 times per day for 6 weeks.","id":"OG002","title":"Pilocarpine 4 Times Per Day"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"End of 6 weeks","title":"Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) 3.0","type":"SECONDARY","unitOfMeasure":"participants"}